SANTA FE, NM / March 24, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs”), a leading developer of quality assurance software for the commercial 3D printing industry, reported its financial and operational results for the fourth quarter and full year ended December 31, 2019.
Key Fourth Quarter and Subsequent Operational Highlights
- Entered into joint sales agreement with Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and 3D printing solutions, to commercialize newly integrated PrintRite3D quality assurance technology with the Materialise control platform.
- Awarded Phase 2 test and evaluation program of PrintRite3D® in-process quality assurance software on two 3D printers from different manufacturers by a leading global energy technology company, following a successful Phase 1 completion.
- Customer provides technology and services that enable oil and gas companies in over 120 countries to deliver safe, affordable energy to the world.
- Selected by major Japanese OEM machine tool manufacturer for a test and evaluation program of PrintRite3D Real Time Melt Pool Analytics at OEM’s R&D center in Japan.
- Announced several key contract wins to further validate the Company’s technology, including:
- Contract to implement PrintRite3D in collaboration with university research centers at the Northwestern University, Northwestern Initiative on Manufacturing Science and Innovation (NIMSI) and Center for Hierarchical Materials Design (CHiMaD).
- Contract with the Mississippi State University Center for Advanced Vehicular Systems (CAVS), a world-class interdisciplinary research center that uses state-of-the-art technology to address engineering challenges facing U.S. mobility industries.
- Contract with the VTT Technical Centre of Finland to install PrintRite3D at the VTT 3DMetalprint Centre for Additive Manufacturing, enabling VTT to best support its customers development activities.
- Awarded PrintRite3D upgrade contract by the Fraunhofer Research Institution for Additive Manufacturing Technologies, an additive manufacturing research innovator and early adopter of PrintRite3D, to update the software and hardware to the current version 5.1 system.
- Appointed accomplished software executive Mark K. Ruport as Executive Chairman to drive formation of strategic relationships, growth and sales strategies.
- Chief Technology Officer Darren Beckett demonstrated PrintRite3D on-site and spoke at Formnext 2019 – the leading global exhibition on additive manufacturing and the next generation of intelligent industrial production in Frankfurt, Germany on November 19-22, 2019.
- CTO Darren Beckett also presented on the integration of PrintRite3D into Materialise’s MCP control system in the Materialise (NASDAQ: MTLS) Booth at Formnext 2019.
- PrintRite3D Patent Estate: Expanded its robust intellectual property portfolio to 11 issued and 24 pending patents both domestically and internationally, with notices of allowance for two issued patents received as recently as March 18, 2020.
Full Year 2019 Operational Highlights
- Selected by a major international OEM machine manufacturer to integrate the PrintRite3D® quality assurance software program as part of an evaluation process for a broader rollout.
- Selected by Airbus (AIR:FP / OTC: EADSY), a global leader in aeronautics, space and related services to deploy the PrintRite3D version 5.0 software product into a laser powder bed printer as part of a testing and evaluation program.
- Realized third-party validation of Sigma Labs’ proprietary PrintRite3D® quality assurance software through a Defense Advanced Research Project Agency (DARPA) research study conducted in collaboration with Honeywell Aerospace.
- Joined the Additive Alliance of Fraunhofer IAPT as well as the U.K-based Manufacturing Technology Centre, leading global additive manufacturing networks, to further expand business development and partnership opportunities.
- Appointed Frank D. Orzechowski as Chief Financial Officer effective July 1, 2019. The 30-year financial and operational veteran has led large teams through significant corporate transactions, including mergers and acquisitions, financings and other transactions during his career.
- Presented at multiple investor and industry conferences to strengthen the company’s commercial and investor presence, including:
- Engaged leading international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets.
Management Commentary
“2019 was a milestone year for Sigma Labs, as we transitioned from an R&D focused company into a full-fledged commercial enterprise – complete with a validated, user-friendly product with customers who are some of the largest industrial companies in the world and in the top echelon of additive manufacturing OEMs,” said Mark Ruport, Executive Chairman of Sigma Labs.
“I am particularly proud of our recently announced joint sales agreement with Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and 3D printing solutions, to commercialize our newly integrated PrintRite3D quality assurance technology within the Materialise control platform. I continue to see intense interest from industry players of every size, proving the absolute value inherent to our technology.
“Due to the success of our RTE program we are transitioning to full commercialization of PrintRite3D. The market has validated the need for a 3rd party quality assurance solution that is capable of working with multiple 3D printers, including single, dual and quad laser configurations, from different manufacturers. Our RTE customers have tested and confirmed PrintRite3D Version 5’s ability to detect and classify defeats and anomalies. The lack of a 3rd party in-process quality assurance has been seen as a major barrier to full industrialization of additive manufacturing. PrintRite3D is seen by many as the only product capable of providing a standard assessment of quality in such diverse heterogeneous environments
“A key asset that continues to provide us with a strong competitive moat as we ramp up commercialization is our robust intellectual property portfolio, comprised of numerous trade secrets, eleven patents granted, and 24 pending in both the U.S. and around the globe,” continued Ruport.
“Sigma is truly on the forefront of the next industrial revolution, addressing a major cost headwind to allow additive manufacturing technology to further scale and revolutionize many industries. We continue to see momentum from both end-users, who constantly serve as a reminder of the value of our technology, and from additive manufacturing machine OEMs, who see inherent value in integrating PrintRite3D into their machines. Revenues from either of these avenues could build rapidly, but more importantly could provide for a repeatable revenue stream with exceptional gross margins.
“Finally, I’d be remiss if I didn’t acknowledge that the crisis that the world is facing at this very moment in time, is and will continue for the foreseeable future to affect all of our business and personal plans in ways that we can’t predict. Our principal commitments are to our employees and their families, our shareholders and our customers. As events unfold we will take the steps necessary to do everything within our power to move forward and continue to execute on strategic initiatives all over the world, working towards our goal of setting the standard for quality assurance in the exciting commercial 3D printing industry,” concluded Ruport.
Fourth Quarter and Full Year 2019 Financial Results
Revenue for the full year of 2019 totaled $402,000, of which $133,000, or 33% was earned in the fourth quarter. This compares to revenues of $388,000 for the full year of 2018, of which $56,000 was earned in the fourth quarter.
Gross profit for the full year of 2019 was negative $172,000, of which the fourth quarter contributed negative $105,000. The company’s 2019 gross margin is primarily a function of variable additional travel and labor costs associated with the on-site and remote collaboration involved in the Company’s Rapid Test and Evaluation program.
Total operating expenses for 2019 were $6.2 million, of which $1.5 million were incurred in the fourth quarter. Total operating expenses for 2018 totaled $ $5.7 million. The increase in total operating expenses was primarily driven by increases in salaries and benefits of $525,000 and occupancy and general office expenses of $57,000 related to six new hires, increased research and development expenses of $155,000 related to the continued development of our PrintRite3D® product suite, and increased travel expenses of $93,000 related to continued outreach to prospective OEM, service bureau and end user customers and our ongoing expansion into the European market. Partially offsetting these increases was a reduction in stock-based compensation expense of $348,000.
Cash used in operating activities for the full year ended December 31, 2019 totaled $5.5 million, compared to $3.8 million in the full year ended December 31, 2018. Cash used in operating activities totaled $1.0 million for the fourth quarter of 2019, as compared to $1.1 million in the fourth quarter of 2018.
Net loss for the full year of 2019 was $6.3 million, or $(5.37) per share, as compared to a net loss of $5.6 million, or $(8.10) per share, in 2018. Net loss in the fourth quarter of 2019 totaled $1.6 million, or $(1.17) per share, compared to a net loss of $1.7 million, or $(2.01) per share, in the fourth quarter of 2018.
Cash totaled $0.1 million at December 31, 2019, as compared to $1.1 million at September 30, 2019 and $1.3 million at December 31, 2018. Subsequent to the close of the fourth quarter, the Company completed two private placements consisting of shares of convertible preferred stock, warrants to purchase additional shares of convertible preferred stock, and warrants to purchase shares of our common stock, resulting in net cash proceeds to us of approximately $1.7 million. If all of the remaining warrants to purchase shares of preferred stock and common stock are exercised for cash by the holders, the potential gross proceeds to us will be $13.8 million.
“While the current business environment caused by the COVID-19 pandemic is concerning, we remain resilient and our employees maintain full capability when working remotely. We have restricted all non-essential travel and we expect minimal disruption to our operations as a result of the nature of our business and precautions we have put in place,” added Frank Orzechowski, Chief Financial Officer.
Fourth Quarter and Full Year 2019 Results Conference Call
Sigma Labs Executive Chairman Mark Ruport, CEO John Rice and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.
To access the call, please use the following information:
| Date: |
Tuesday, March 24, 2020 |
| Time: |
4:30 p.m. Eastern time, 1:30 p.m. Pacific time |
| Toll-free dial-in number: |
1-877-407-9039 |
| International dial-in number: |
1-201-689-8470 |
| Conference ID: |
13700105 |
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=138447 and via the investor relations section of the Company’s website at www.sigmalabsinc.com.
A replay of the conference call will be available after 7:30 p.m. Eastern time through April 7, 2020.
| Toll-free replay number: |
1-844-512-2921 |
| International replay number: |
1-412-317-6671 |
| Replay ID: |
13700105 |
About Sigma Labs
Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on March 24,2020 and which may be viewed at www.sec.gov.
Investor Contact:
Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us
Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)
|
|
December 31,
2019 |
|
|
December 31,
2018 |
|
|
ASSETS
|
|
|
|
|
|
|
|
Current Assets:
|
|
|
|
|
|
|
|
Cash
|
|
$ |
86,919 |
|
|
$ |
1,279,782 |
|
|
Accounts Receivable, net
|
|
|
55,540 |
|
|
|
38,800 |
|
|
Note Receivable, net
|
|
|
– |
|
|
|
121,913 |
|
|
Inventory
|
|
|
598,718 |
|
|
|
240,086 |
|
|
Prepaid Assets
|
|
|
199,727 |
|
|
|
67,255 |
|
|
Total Current Assets
|
|
|
940,904 |
|
|
|
1,747,836 |
|
|
|
|
|
|
|
|
|
|
|
Other Assets:
|
|
|
|
|
|
|
|
|
|
Property and Equipment, net
|
|
|
128,723 |
|
|
|
277,944 |
|
|
Intangible Assets, net
|
|
|
569,341 |
|
|
|
404,978 |
|
|
Investment in Joint Venture
|
|
|
500 |
|
|
|
500 |
|
|
Long-Term Prepaid Asset
|
|
|
52,000 |
|
|
|
– |
|
|
Total Other Assets
|
|
|
750,564 |
|
|
|
683,422 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$ |
1,691,468 |
|
|
$ |
2,431,258 |
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
$ |
727,114 |
|
|
$ |
217,488 |
|
|
Note Payable
|
|
|
50,000 |
|
|
|
50,000 |
|
|
Deferred Revenue
|
|
|
139,447 |
|
|
|
51,498 |
|
|
Accrued Expenses
|
|
|
122,658 |
|
|
|
376,833 |
|
|
Total Current Liabilities
|
|
|
1,039,219 |
|
|
|
695,819 |
|
|
|
|
|
|
|
|
|
|
|
Long-Term Liabilities
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
|
|
1,039,219 |
|
|
|
695,819 |
|
|
|
|
|
|
|
|
|
|
|
Commitments & Contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.001 par; 10,000,000 shares authorized; none issued and outstanding
|
|
|
– |
|
|
|
– |
|
|
Common Stock, $0.001 par; 2,250,000 shares authorized; 1,403,759 and 877,663 issued and outstanding, respectively
|
|
|
1,404 |
|
|
|
878 |
|
|
Additional Paid-In Capital
|
|
|
26,746,439 |
|
|
|
21,509,306 |
|
|
Accumulated Deficit
|
|
|
(26,095,594 |
) |
|
|
(19,774,745 |
) |
|
Total Stockholders’ Equity
|
|
|
652,249 |
|
|
|
1,735,439 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
$ |
1,691,468 |
|
|
$ |
2,431,258 |
|
Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)
|
|
Years Ended |
|
|
|
December 31,
2019 |
|
|
December 31,
2018 |
|
|
REVENUES
|
|
$ |
402,446 |
|
|
$ |
388,574 |
|
|
|
|
|
|
|
|
|
|
|
COST OF REVENUE
|
|
|
574,301 |
|
|
|
270,107 |
|
|
|
|
|
|
|
|
|
|
|
GROSS PROFIT
|
|
|
(171,855) |
|
|
|
118,467 |
|
|
|
|
|
|
|
|
|
|
|
EXPENSES:
|
|
|
|
|
|
|
|
|
|
Salaries & Benefits
|
|
|
2,354,329 |
|
|
|
2,056,584 |
|
|
Stock-Based Compensation
|
|
|
797,238 |
|
|
|
1,145,530 |
|
|
Operating R&D Costs
|
|
|
647,994 |
|
|
|
493,410 |
|
|
Investor & Public Relations
|
|
|
703,710 |
|
|
|
633,035 |
|
|
Legal & Professional Service Fees
|
|
|
664,403 |
|
|
|
564,854 |
|
|
Office Expenses
|
|
|
692,881 |
|
|
|
466,657 |
|
|
Depreciation & Amortization
|
|
|
192,569 |
|
|
|
192,374 |
|
|
Other Operating Expenses
|
|
|
158,706 |
|
|
|
134,827 |
|
|
Total Operating Expenses
|
|
|
6,211,830 |
|
|
|
5,687,271 |
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
(6,383,685 |
) |
|
|
(5,568,804 |
) |
|
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE)
|
|
|
|
|
|
|
|
|
|
Interest Income
|
|
|
18,760 |
|
|
|
35,178 |
|
|
State Incentives
|
|
|
51,877 |
|
|
|
– |
|
|
Bad Debt Expense
|
|
|
(2,500 |
) |
|
|
– |
|
|
Exchange Rate Gain (Loss)
|
|
|
(4,879 |
) |
|
|
162 |
|
|
Other Income
|
|
|
8,263 |
|
|
|
– |
|
|
Interest Expense
|
|
|
(8,685 |
) |
|
|
(3,966 |
) |
|
Loss on Disposal of Assets
|
|
|
– |
|
|
|
(36,733 |
) |
|
Total Other Income (Expense)
|
|
|
62,836 |
|
|
|
(5,359) |
|
|
|
|
|
|
|
|
|
|
|
LOSS BEFORE PROVISION FOR INCOME TAXES
|
|
|
(6,320,849) |
|
|
|
(5,574,163) |
|
|
|
|
|
|
|
|
|
|
|
Provision for Income Taxes
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$ |
(6,320,849) |
|
|
$ |
(5,574,163) |
|
|
|
|
|
|
|
|
|
|
|
Preferred Dividends
|
|
|
– |
|
|
|
(15,125 |
) |
|
|
|
|
|
|
|
|
|
|
Net Loss applicable to Common Stockholders
|
|
$ |
(6,320,849) |
|
|
$ |
(5,589,288) |
|
|
|
|
|
|
|
|
|
|
|
Net Loss per Common Share – Basic and Diluted
|
|
$ |
(5.37) |
|
|
$ |
(8.10) |
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Number of Shares Outstanding – Basic and Diluted
|
|
|
1,176,278 |
|
|
|
689,805 |
|
Sigma Labs, Inc.
Condensed Statements of Cash Flows
(Unaudited)
|
|
Years Ended |
|
|
|
December 31,
2019 |
|
|
December 31,
2018 |
|
|
OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
Net Loss
|
|
$ |
(6,320,849 |
) |
|
$ |
(5,574,163 |
) |
|
Adjustments to reconcile Net Loss to Net Cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
Noncash Expenses:
|
|
|
|
|
|
|
|
|
|
Depreciation and Amortization
|
|
|
192,569 |
|
|
|
192,374 |
|
|
Stock Based Compensation
|
|
|
797,240 |
|
|
|
1,145,530 |
|
|
Stock Issued for Third Party Services
|
|
|
17,110 |
|
|
|
– |
|
|
Warrants Issued for Third Party Services
|
|
|
15,569 |
|
|
|
– |
|
|
Loss on Write-off of Asset
|
|
|
– |
|
|
|
36,733 |
|
|
Change in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts Receivable
|
|
|
(16,740 |
) |
|
|
65,738 |
|
|
Interest Receivable
|
|
|
– |
|
|
|
34,390 |
|
|
Inventory
|
|
|
(358,632 |
) |
|
|
(24,844 |
) |
|
Prepaid Assets
|
|
|
(184,472 |
) |
|
|
(1,652 |
) |
|
Accounts Payable
|
|
|
509,626 |
|
|
|
116,604 |
|
|
Deferred Revenue
|
|
|
87,949 |
|
|
|
15,818 |
|
|
Accrued Expenses
|
|
|
(254,175 |
) |
|
|
230,501 |
|
|
NET CASH USED IN OPERATING ACTIVITIES
|
|
|
(5,514,805) |
|
|
|
(3,762,971) |
|
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
Purchase of Property and Equipment
|
|
|
(33,487 |
) |
|
|
(79,116 |
) |
|
Purchase of Intangible Assets
|
|
|
(174,224 |
) |
|
|
(149,409 |
) |
|
Payment Received from Notes Receivable
|
|
|
121,913 |
|
|
|
632,197 |
|
|
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
|
|
|
(85,798) |
|
|
|
403,672 |
|
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
Gross Proceeds from issuance of Convertible Preferred and Warrants
|
|
|
– |
|
|
|
1,350,000 |
|
|
Gross Proceeds from issuance of Common Stock and Warrants
|
|
|
4,981,221 |
|
|
|
2,040,100 |
|
|
Less Offering Costs
|
|
|
(649,329 |
) |
|
|
(433,700 |
) |
|
Proceeds from exercise of Warrants
|
|
|
75,848 |
|
|
|
192,132 |
|
|
Dividends on Preferred
|
|
|
– |
|
|
|
(15,125 |
) |
|
NET CASH PROVIDED BY FINANCING ACTIVITIES
|
|
|
4,407,740 |
|
|
|
3,123,407 |
|
|
|
|
|
|
|
|
|
|
|
NET CHANGE IN CASH FOR PERIOD
|
|
|
(1,192,863) |
|
|
|
(235,892) |
|
|
|
|
|
|
|
|
|
|
|
CASH AT BEGINNING OF PERIOD
|
|
|
1,279,782 |
|
|
|
1,515,674 |
|
|
|
|
|
|
|
|
|
|
|
CASH AT END OF PERIOD
|
|
$ |
86,919 |
|
|
$ |
1,279,782 |
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures:
|
|
|
|
|
|
|
|
|
|
Noncash investing and financing activities disclosure:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of Convertible Debt for Stock
|
|
$ |
– |
|
|
$ |
(50,000 |
) |
|
Common Stock Issued for Conversion of Series B&C Preferred
|
|
|
– |
|
|
|
1,350 |
|
|
Common Stock Issued for Cashless Exchange of Warrants
|
|
|
– |
|
|
|
5 |
|
|
Common Stock Issued for Cashless Exchange of Unit Purchase Options
|
|
|
88 |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
Other noncash operating activities disclosure:
|
|
|
|
|
|
|
|
|
|
Issuance of Common Stock and Warrants for services
|
|
$ |
335,679 |
|
|
$ |
256,264 |
|
|
|
|
|
|
|
|
|
|
|
Disclosure of cash paid for:
|
|
|
|
|
|
|
|
|
|
Interest
|
|
$ |
5,069 |
|
|
$ |
12,205 |
|
|
Income Taxes
|
|
$ |
– |
|
|
$ |
– |
|
SOURCE: Sigma Labs, Inc.
March 20, 2020
- Major first-mover advantage in proprietary web-based e-commerce platform segment
- Penetrating U.S. independent pharmacy market with total purchases of $92 billion per annum
- Adding 100+ pharmacies per month to its online purchasing platform
Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and health care platform that offers health care buyers and sellers of pharmaceuticals procurement, currently has more than 11,900 pharmacies as registered users of its proprietary e-commerce platform. Registered users are under no contract of fee obligations when joining the ‘Supplier-to-Pharmacy’ (S2P) trading platform.
With the current number of users already on the network – serving an estimated 12 to 15 million patients indirectly through these member pharmacies , and adding about 100 new pharmacies per month, Trxade’s goal is to reach most, if not all, of the 24,000 independent pharmacies in the U.S., which have a combined annual purchasing power of more than $92 billion.
Leveraging a robust technology with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features, the platform is designed to help independent pharmacies identify the best available supplier prices for prescription drugs nationwide. The platform allows its members to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.
This approach is part of Trxade’s efforts to be one of the driving forces behind a nationwide reduction of pharmaceutical and health care costs. To this end, the company is committed to developing its portfolio of products and services to drive value and growth for all members, employees and investors. Trading platform aside, Trxade also owns a mail order pharmacy and warehouse and drug delivery service through our Delivemeds (www.Delivmeds.com) and Bonum Health (www.BonumHealth.com) a Telehealth App.
The company recently launched a one-of-a-kind Telehealth initiative, called the ‘Bonum Health Hub’, together with wholly owned subsidiary Bonum Health, which partnered with Tampa Bay-based independent retail pharmacy chain Benzer Pharmacy. Bonum and Benzer will locate the Health Hubs in urban and rural areas lacking this type of care. The Hubs will provide capacities and technology to offer care to patients who can afford neither primary nor collaborative care.
The U.S. health care market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Drug costs are expected to increase faster than overall health care costs and well above inflation. Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.
For more information, visit the company’s website at www.TrxadeGroup.com
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
- Pharmaceutical services business Trxade Group Inc. recently announced its uplisting to the Nasdaq Capital Market and will ring the exchange’s opening bell this Friday, February 28, 2020
- The ringing of the opening bell will be broadcast live at 9:30 a.m. EST from the Nasdaq’s Times Square market site in New York City
- The company will cease trading on the OTC market and phase out its ‘TRXD’ ticker as part of the move, transitioning to new Nasdaq ticker ‘MEDS’
- Trxade Group is a pioneer in building a supplier-to-pharmacy platform that helps small, independent businesses be competitive with larger chains by sourcing drugs at discount prices, building consumer confidence through transparency in operations
- The company’s network of pharmaceutical partners continues to expand, aiming to eventually reach most, if not all, of the nation’s 24,000 independent pharmacies
Pharmacy services B2B innovator Trxade Group Inc. (NASDAQ: MEDS) will ring the Nasdaq opening bell Friday, February 28, to celebrate the supplier-to-pharmacy business’s uplisting to the Capital Market exchange, which the company announced February 13.
As one circumstance of the move, Trxade will begin trading under the ticker MEDS and will phase out its previously existing OTC common stock symbol, ‘TRXD’. The iconic ringing of the bell represents a significant milestone for companies and an opportunity for them to celebrate their achievements in front of a global audience. The bell ringing will be broadcast live via satellite at 9:30 a.m. from the Nasdaq’s Time Square market site in New York City, following an hour of lead-up promotional events with Nasdaq senior executives.
“We’ve been under the radar for a long time. We’re trying to create visibility among the investor base by doing the right thing,” CEO Suren Ajjarapu stated late last year following completion of an agreement between its subsidiary Bonum Health and Benzer Pharmacy to create a network of ‘Bonum Health Hub’ units in small towns and rural areas as part of the lead-up to the Nasdaq listing (http://nnw.fm/S6Nai).
The company recently completed a firm commitment public offering of 806,452 shares of its common stock following a voter-approved reverse stock split. Trxade expects to gain gross proceeds of $5.2 million from the sale of common stock in the offering, minus standard expenses tied to the offering.
Trxade Group relishes its role as a health care industry influencer intent on enabling price transparency and increased profit margins to health care buyers and sellers of pharmaceuticals, particularly the nation’s independent pharmacies that serve small, close-knit communities.
The company anticipates using the net proceeds of the public offering for its own general corporate purposes and possibly to fund acquisitions of other companies, products or technologies – part of Trxade’s strategy for increasing shareholder value and advancing its business model.
Trxade’s network of platform clients includes nearly 11,900 independent pharmacies registered and the company aims to continuously grow the size of the network until most, if not all, of the nation’s 24,000 independent pharmacies are represented with a combined annual purchasing power of more than $92 billion to help them compete with larger pharmaceutical companies.
“During the third quarter of 2019, we made excellent progress in our core proprietary B2B trading platform www.trxade.com, which enables independent pharmacies to purchase drugs at discount prices compared to their primaries, enabling us to experience top and bottom line growth,” Ajjarapu stated (http://nnw.fm/3pyW9). “Additionally, we are investing in core infrastructure for our B-to-C (Community Specialty Pharmacy) business in our wholesale, e-commerce and delivery capabilities as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing medication.”
For more information, visit the company’s website at www.TrxadeGroup.com
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
- Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases
- Predictive Oncology launches new AI platform in fight against new pathogens
- Artificial intelligence likely to help find COVID-19 vaccines and therapeutics
With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced it was entering the fight against the latest scourge and is launching a new artificial intelligence platform to aid in vaccine and drug development to battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) (http://nnw.fm/3uS2j).
Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates.
“The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,” HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://nnw.fm/3uS2j). DeLucas, who flew aboard NASA Space Shuttle mission STS-50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.
Global health experts predict an ever-increasing number of viral outbreaks like COVID-19, and POAI intends to be at the forefront of efforts to identify and aid in the development of new vaccines and therapeutics. Predictive Oncology has enjoyed a business relationship with InventaBioTech and through negotiations signed a letter of intent to acquire Soluble Therapeutics, its assets and, most importantly, its HSC(TM) Technology. The technology dovetails POAI’s efforts against cancer as the HSC(TM) machines can be used in the development of new cancer antibodies and vaccines and create new possibilities in the fight against new pathogens. Soluble Therapeutics has previously worked with many of the major pharmaceutical companies searching for a vaccine such as Gilead Sciences (NASDAQ: GILD), GlaxoSmithKline (NYSE: GSK), Pfizer, Bayer and others.
The HSC(TM) Instrument and underlying technology have been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.
The HSC(TM) Technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. Able to do more with less, the technology only requires milligrams of material, where a traditional formulation effort can require up to a gram. Two decades in the making, HSC Technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pathogens, battle cancers, and enhance the drug development process by rapidly optimizing protein solubility and stability. Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics’ technology directly addresses this obstacle.
Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a rapid AI discovery platform that quickly and cost-effectively identifies potential vaccines and therapeutic candidates as well as optimizing protein formulations for stability and higher protein concentrations using FDA approved ingredients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
COLUMBUS, March 19, 2020 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or the “Company“) announced today that Peter Horvath is stepping down as Chief Executive Officer and as a member of the Board of Directors effective today. Mr. Horvath has served as CEO of the Company since January 2019 and as a member of the Company’s Board of Directors since July 2018. Randy Whitaker, the Company’s current Chief Operating Officer will take over as interim Chief Executive Officer, effective immediately. Mr. Whitaker has served as the Company’s Chief Operating Officer since February 2019. The vacancy on the Company’s Board of Directors will be filled in due course.
Ms. Carli Posner, the Chair of the Board of Directors, said “On behalf of the Board and everyone at GGB, I would like to offer my heartfelt thanks to Peter for his significant contribution and dedication to the Company and wish Peter the best for his future endeavours.”
Mr. Horvath responded, “I am humbled to have worked with such amazing professionals along this journey. Among those individuals is Randy Whitaker, whom I am pleased has been named as interim CEO. The Company will be in good hands with such a seasoned operator at the helm, and I have full confidence in Randy to lead the Company during this difficult time.”
Corporate Update
In response to the ongoing COVID-19 pandemic and in accordance with the recommendations of health professionals and other mall-based retailers, the Company has elected to temporarily close all of its mall-based cannabidiol (“CBD“) kiosk shops in an effort order to protect its employees and customers from unnecessary exposure to the COVID-19 virus. In connection with this action, the Company will also suspend sales under its CBD e-commerce platform.
The Company’s cannabis dispensaries, located in the Las Vegas, Nevada area, will remain open for business subject to additional pandemic-related directives from local authorities. The Company will continue to employ best practices and adhere to such directives related to its operations in light of the COVID-19 pandemic.
The Company will continue to pursue the previously announced sale of the CBD business to The BRN Group Inc. In connection therewith, the Company will continue to solicit and evaluate any potential superior offers under the go-shop rights afforded to the Company as part of that announced transaction.
About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. The company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and 8 Fold. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. Learn more about the vision at GreenGrowthBrands.com.
Cautionary Statements
Forward Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in (i) the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR and (ii) the Company’s Short Form Prospectus dated August 15, 2019. Information relating to the Company’s second quarter results in this news release is based upon unaudited internal financial statements prepared by management and subject to final review procedures.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including without limitation, the the successful completion of the sale of the CBD business, including to The BRN Group Inc., is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Going Concern Risk
As previously disclosed, the continuing operations of the Company remain dependent upon its ability to continue to raise adequate financing, to commence profitable operations in the future, and repay its liabilities arising from normal business operations as they become due. Notwithstanding the strategic review of the CBD Business there remains a significant risk that the Company will be unable to realize sufficient cost savings, find sufficient sources of financing for on-going working capital requirements and maturing debt and other liabilities or to negotiate extensions or alternate payment terms in respect of such debt. These material uncertainties cast significant doubt upon the Company’s ability to meet its obligations as they come due and to continue as a going concern. As previously announced, US$5 million is payable to Moxie on or before February 5, 2020 (including a five-day cure period following January 31, 2020), and an additional US$2 million is due in installments to ABG-Shark LLC related to the GMR Payment on or before March 31, 2020. The Company is working to negotiate a deferral of these obligations and has previously announced short-term financing from certain of its key stakeholders in connection therewith. In addition to the Moxie and ABG-Shark payments, the Company and its subsidiaries have material obligations that are due or that are coming due within the next 15 to 45 days. The Company has drawn all amounts available to it under the previously announced working capital backstop commitment provided by All Js Greenspace LLC (“All Js”) and Chiron Ventures Inc. (collectively, the “Backstop Parties”) for purposes of funding the Company’s operations. In addition, for purposes of funding the Company’s operations All Js advanced approximately US$1.5 million from its portion of the previously announced US$52.3 million debenture repayment backstop commitment. Notwithstanding this US$1.5 million advance from All Js, there is no guarantee that either of the Backstop Parties will permit additional funds to be drawn from the debenture repayment backstop commitment for purposes of funding the Company’s operations. Amounts drawn from the debenture backstop commitment to fund operations reduce the funds available to refinance the debentures upon maturity. The Company is actively pursuing alternative financing sources but there can be no guarantee that any such financing will be consummated or if consummated on what terms.
Investors are cautioned that additional financing may not be available when needed or, if available, the terms of such financing might not be favourable to the Company and might involve substantial dilution to existing shareholders. Failure to raise capital when needed will have a material adverse effect on the Company’s ability to pursue its business strategy, and accordingly could negatively impact the Company’s business, financial condition and results of operations. Failure to obtain sufficient debt or equity financing and/or to successfully executed on one or more strategic alternative transactions could result in the Company defaulting on its obligations and force the Company into reorganization, bankruptcy or insolvency proceedings.
US Securities Law Disclaimer
This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.
The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.
March 2, 2020
- On-demand 3D printing revolutionizing supply chain dynamics for manufacturing industry
- SGLB is sole provider of urgently needed software solution that uniquely addresses in-process quality-control issues for 3D metal printing
- Provision of quality-assurance software is valued at more than $1.4 billion, expected to grow to $3.9 billion by 2023
Referenced as one of tomorrow’s “greatest conduits for converting scarcity to abundance,” the 3D printing industry is transforming the $12 trillion manufacturing landscape while simultaneously disrupting the supply chain model (http://nnw.fm/yUi8A). At the frontline of the movement is Sigma Labs Inc. (NASDAQ: SGLB), the industry’s sole provider of quality-control software that puts more control of the 3D-printing metal process into the operator’s hands for the purpose of eliminating inefficiencies, reducing rejected output, and saving time and money.
Traditional metal machining manufacturers mostly carve, slice and grind away at raw materials to produce their products (called ‘subtractive manufacturing’) while the 3D metal printing process (also called additive manufacturing) creates objects by laser sintering powdered metals layer by 10-30 micron layer on top of each other using a computer-aided design (CAD) model and formed into the desired three dimensional object. Since the objects are built in layers, customizations are made by altering instructions in the digital file. Unfortunately, errors made during production are not found until after the process is complete, which results in excessive cost and material waste.
SGLB addresses this crucial issue through proprietary software solutions that enable operators to monitor the production process in real time and receive notifications about errors or anomalies while the process is taking place. This gives operators the knowledge required to make changes in real time, enabling them to avoid the creation of flawed output while producing yields of consistent high quality.
The demand for quality-control software increases as the production process becomes more complex. Two decades ago, 3D printers cost several hundred thousand dollars and used only plastic; today’s machines are 150 times faster and can print items using more than 500 different materials across the entire periodic table of elements.
While the first items printed were simple household items, before long, 3D printers were creating prosthetic limbs, rocket engines and car parts. However, as the uses for 3D printers increased, so also did quality-control challenges. The increased complexity of the production process demands better quality control, and SGLB has focused on software solutions for the industry. To date, SGLB has 19 beta programs in place with some of the largest names in industry – obtaining many tier-1 OEM enterprises such as GE Aviation, Honeywell and Airbus in the process.
Originally founded in 2010 by a team of Los Alamos National Labs scientists and engineers, SGLB first operated as a developer of commercially licensed, advanced metallurgical products. Forecasting high demand for quality-control solutions in the 3D-metal-printing space, the company shifted its operations to creating in-process quality-control software solutions for highly demanding, precision-dependent companies in the aerospace, defense, transportation, oil and gas, and biomedical industries.
The provision of quality-assurance software to the commercial, 3D-metal-printing industry is valued at over $1.4 billion and expected to explode to $3.9 billion by 2023. As the sole provider of innovative software solutions that address this demand, SGLB is likely to benefit from this unmet need while securing itself as a leader in what many are calling “the fourth industrial revolution.”
For more information about Sigma Labs, please visit www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 17, 2020
- Data shows that 83% of global Internet users regularly share online content on a monthly basis
- Internet users are turning toward online communities as places where they can express themselves
- Jerrick’s Vocal platform, along with its Vocal+ premium-subscription membership program, ranks among top online creator platforms
Online communities are on the rise, according to a recent report released by GlobalWebIndex and Reddit. The report, titled “The era of We and the rise of online communities,” notes that Online community sites have become the go-to platforms for the growing amount of user-generated content posted online (http://nnw.fm/MVks6). Jerrick Media Holdings Inc. (OTC: JMDA) and its proprietary publishing platform Vocal are leading the way in this growing trend.
“We’re now sharing huge amounts of content online – from photos and videos to product reviews,” the study reported. “Our data shows that in 2019, 83% of global Internet users regularly share this kind of information online on a monthly basis, and this is a truly cross-demographic activity, ranging from 70% of Boomers to almost 90% of Gen Z and Millennials.”
Though much of this content was historically shared on social media sites such as Facebook, Instagram and Twitter, along with video sites such as YouTube, the report noted that what the online community is sharing – and where it is shared – is changing.
“For authentic connections, Internet users are increasingly turning toward online communities as places where they can express themselves,” the report states. “In the U.S., 64% of online community site visitors say they’re visiting those sites more often now than they did a couple of years ago, and 46% say the sites have become more important to them over time. Online communities provide a place for genuine human connection and belonging in the digital world. On them, we can meet people who share our interests, learn from others, and have meaningful conversations.”
That’s precisely the type of community that creators and community members find on Vocal. Jerrick’s online platform is built on the idea of community of individuals, businesses and audiences brought together by a common interest or goal. Vocal’s genre-specific communities (http://nnw.fm/4QamP) span topics ranging from health and wellness to beauty, food, women’s issues, gaming, mental health, and more. Individuals use these virtual communities of transaction to buy, sell or learn more about products and services; to discuss shared interests; to develop social relations; and to explore new identities.
Savvy brands that tap into these powerful virtual communities, such as through Vocal’s branded content studio, Vocal for Brands (http://nnw.fm/kv1lT), can experience significant benefits, including increased sales, positive word‐of‐mouth, more effective market segmentation, increased website traffic, stronger brand, higher advertising and transaction fee revenue, and better product support and service delivery.
“These spaces offer marketers an opportunity to connect with consumers in a more meaningful and authentic way,” the report said. “Online communities have become an important touchpoint across the consumer journey, especially among younger generations – and our research shows that there’s a big appetite among the majority of online community participators for brands to join the conversation and have a voice. This marketing channel offers brands a way of staying ahead of emerging expectations, giving consumers a sense of involvement, and ultimately deepening their connection with today’s consumers.”
Jerrick’s Vocal platform, which includes a premium membership program called Vocal+ (http://nnw.fm/H7yiG), ranks among the top online creator platforms in the digital world, with approximately 565,000 registered creators to date. “Vocal is a technology platform that is of a caliber associated with only a few hundred other digital platforms,” Jerrick CEO Jeremy Frommer stated in a news release (http://nnw.fm/I8rpq), who noted that the company spent nearly six years studying and researching in order to create the platform.
Jerrick Media Holdings is focused on the development of digital communities, targeted marketing of branded digital content and e-commerce opportunities. To accomplish these objectives, Jerrick envisions, designs and builds modern technology companies that redefine how people interact with technology. As the parent company of Vocal, Jerrick has built and shipped products that have influenced millions of people worldwide.
Those interested in weekly news from Jerrick can sign up at http://nnw.fm/hTp91
For more information, visit the company’s website at https://Jerrick.media
NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://nnw.fm/JMDA
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 17, 2020
- Artificial intelligence (AI) at forefront of scientific discovery, proving importance in fighting complex diseases
- Science turns to AI as effective tool to help find COVID-19 vaccines and therapeutics
- Predictive Oncology harnesses power of AI to improve cancer patient outcomes
With the global onslaught of COVID-19, scientists are harnessing the speed and power of artificial intelligence (AI) to find solutions. The complexity of this lethal contagion demands a rapid yet comprehensive response, and only advanced computer systems can parse through mountains of data sets swiftly enough to stem the pandemic. AI’s ability to sort and sift data quickly, spot patterns and make predictions can help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) is utilizing its proprietary AI solutions to understand and battle cancer – positioning the company as an attractive option for investors looking to invest in the future of cutting-edge medicine. These same AI solutions may be utilized to help find COVID-19 vaccines and therapeutics.
Through its subsidiary Helomics, a leader in AI and functional precision medicine, POAI is bringing its innovative technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.
The power and utility of artificial intelligence was delineated in a recent Wall Street Journal article titled ‘Biotech Companies Tap AI to Speed Path to Coronavirus Treatments’ (http://nnw.fm/BJ7qk). While drug development – from invention to clinical trials – can take more than a year, health care industry leaders are looking to AI to identify drug prospects to test on humans within months. POAI’s predictive models can be applied clinically to aid patients and in the development of new drugs by researchers.
Aggressive situations like the steady spread of COVID-19, among other fast-moving cancers and diseases, has the global community scrambling for an expedited solution – a problem that AI-powered technology has the potential to help solve. “[COVID-19] is a rapidly developing situation, and we firmly believe that AI-driven experimentation is the right approach for these kinds of problems, to speed up the process,” stated professor Robert Murphy, Ph.D., a recognized expert in AI and computational biology. Dr. Murphy also sits on Predictive Oncology’s advisory board and is the head of the computational biology department in the School of Computer Science at Carnegie Mellon University and co-founder of AI predictive-modeling company Quantitative Medicine LLC.
In a pivotal collaborative move, Predictive Oncology has completed a letter of intent (http://nnw.fm/EC98y) to acquire Quantitative Medicine and integrate its CoRE predictive modeling platform with POAI’s massive historic database and tumor profiling expertise with the aim of revolutionizing the way precision therapies are developed. The acquisition will provide POAI with Quantitative Medicine’s proven machine learning framework, CoRE. A predictive model-building platform for drug screening and optimization campaigns, CoRE uses hybrid machine learning approaches to rapidly build predictive models that spawn specific wet lab experiments. This cutting-edge technology, similar in methodology to the current AI and machine learning approaches now used in the battle against COVID-19, has the potential to expedite POAI’s mission to use AI and machine learning to discover unique solutions to the future of disease.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 17, 2020
- SGLB recently awarded contract by the Mississippi State University Center for Advanced Vehicular Systems to install PrintRite3D software
- PrintRite3D (R) is sole solution for addressing in-process, quality-control issues for 3D metal printing
- Project demonstrates ability of PrintRite3D to serve as real-world testing ground
- Current addressable market for quality-assurance software is $1.4 billion, expected to reach $3.9 billion by 2023
Sigma Labs Inc. (NASDAQ: SGLB), a leading provider of quality-assurance software for the 3D-metal-printing industry, was recently awarded a contract by the Mississippi State University Center for Advanced Vehicular Systems (CAVS), a leading interdisciplinary research center that addresses challenges faced by U.S. mobility industries using state-of-the-art technology. The contract involves the installation of Sigma Lab’s PrintRite3D(R) on a Renishaw AM400 machine, further demonstrating the platform’s interoperability on an increasingly large base of AM machine manufacturers.
PrintRite3D is Sigma Labs’ patented, in-process, quality-assurance software for the commercial 3D-metal-printing industry, aiming to solve the in-process, quality-control issues that impede the industry from moving past the prototype phase. Because the 3D printing process involves the continuous layering of raw materials to form a 3D object, errors are currently found at the end of the production process during the inspection phase – often resulting in rejected output, lost time, wasted materials and lost profits.
PrintRite3D addresses this issue by providing real-time, melt-pool analytics, leveraging thermal signatures to monitor the quality of each part in the production process, layer by layer and in real time. This information allows operators to stop production of a defective part or employ corrections in-process, ultimately solving the quality consistency issues and giving producers the ability to economically scale up production with increased confidence.
CAVS is a world-class, premier automotive research center, employing more than 300 staff and researchers. Through the use of high-performance, computational resources and state-of-the-art analytical tools for modeling, simulation and experimentation, the center aims to solve some of the most pressing engineering challenges facing US mobility industries.
“They have agreed to act as a test bed for new product improvements to PrintRite3D, uniquely allowing us a real-world feedback loop to continuously improve our technology suite,” Sigma Labs Executive Chairman Mark K. Ruport stated in a news release. “I look forward to working with the entire team at CAVS to bring a new level of quality assurance to both their partners and the additive manufacturing industry as a whole.”
Besides partnerships in the educational sector, SGLB has a global client base that includes many tier-1 OEM enterprises and end users such as Siemens, Honeywell, and Pratt & Whitney. The company is currently in the execution and delivery phase of its commercial development with millions of dollars of investment focused on refining the latest version of PrintRite3D and protecting the IP.
Recognized as a technological game changer in the industry, SGLB’s software is being tested at 23 installations across 19 different users – some of which are the most recognized names in the industry. Currently estimated at a $1.4 billion addressable market, the provision of advanced-quality assurance software to the commercial 3D printing industry is expected to grow to $3.9 billion by 2023.
For more information about Sigma Labs, please visit www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 13, 2020
- POAI positioned as leader in using data, artificial intelligence in search for novel effective treatments
- Planned acquisition provides Predictive Oncology with CoRE(TM), a proven machine-learning framework
- Uniting CoRE with proprietary PDx tumor-profiling platform and tumor-data database creates one-of-a-kind, end-to-end “discovery machine”
With its recent proposed acquisition of Carnegie Mellon spin-out Quantitative Medicine, Predictive Oncology Inc. (NASDAQ: POAI), a leader in using data and artificial intelligence (AI) to develop personalized cancer therapies, demonstrates its strong position in assisting in the search for new anti-cancers, anti-virals, antibiotics and vaccines. POAI’s expertise in this area is particularly relevant in light of the current race to learn more about the novel coronavirus 2019-nCoV and identify potential treatments, including vaccines, to fight the COVID-19 disease.
As organizations around the world rush to find ways to slow the spread of the COVID-19 outbreak, the importance of AI and machine learning (ML) in the world of today’s medicine has become increasingly clear (http://nnw.fm/JPuI6). Governments, pharmaceutical companies, universities and others are united in their focus to develop new diagnostics, vaccines and drug therapies aimed at the 2019-nCoV virus.
Announcements from Insilico Medicine and MIT point to the increasing importance of AI and ML in the progress of modern medicine. In addition, both studies relied on AI and ML approaches that are similar to the CoRE technology used by QM, which POAI is working to acquire (http://nnw.fm/G2t12). With an agreement in principal in place, the all-stock acquisition is expected to close this month.
This planned acquisition provides POAI with QM’s proven machine-learning framework, called CoRE. Developed at CMU and exclusively licensed to QM, CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine-learning approaches to rapidly build predictive models to drive wet-lab experimentation.
Uniting the CoRE approach with the proprietary PDx tumor-profiling platform and tumor-data database owned by POAI subsidiary Helomics allows for a one-of-a-kind, end-to-end “discovery machine” (http://nnw.fm/gIXC7). This approach will “rapidly and cost-effectively generate potential therapeutic candidates that demonstrate activity against the disease. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there is already demonstrated activity in preclinical laboratory tests rather than just a computer model.”
Although POAI’s current focus is on cancers, the CoRE discovery machine could easily be utilized in other critical research, including the rapid discovery of therapeutics, such as anti-virals. “Given sufficient resources and access to relevant data, POAI’s CoRE-driven Helomics discovery machine could soon be at the forefront of the fight against these new viruses,” POAI’s release noted.
The impact of this collaboration on the healthcare industry – between POAI’s AI expertise and QM’s CoRe platform – looms large. Insilico Medicine and MIT illustrate the critical part AI and ML play in the process of advancing modern medicine. In its announcement, Insilico Medicine shared molecular structures potentially to targeting the key protein of 2019nCoV. “By making these structures available to the general public, Insilico hopes those who are interested in finding a potential treatment for this viral infection could synthesize and test these molecules,” the announcement said (http://nnw.fm/Kmh1P). Insilico will also “synthesize and test up to 100 molecules using its own resources and the resources generously offered by its closest partners, to contribute to the global effort.”
For its part, MIT used an MI algorithm to identify a powerful new antibiotic compound that “killed many of the world’s most problematic disease-causing bacteria, including some strains that are resistant to all known antibiotics,” MIT researchers announced (http://nnw.fm/Qcr02). “It also cleared infections in two different mouse models. The computer model, which can screen more than a hundred million chemical compounds in a matter of days, is designed to pick out potential antibiotics that kill bacteria using different mechanisms than those of existing drugs.” As healthcare industry leaders continue to harness the power of AI and ML technologies to improve patient outcomes, the demand for reliable, data-rich platforms like that of POAI is only expect to grow.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven predictive models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 13, 2020
- Sigma Labs enters Joint Sales Agreement with industry leader Materialise to integrate, commercialize Sigma Labs’ Quality Assurance technology
- Momentous industry collaboration validates 3rd party in-process quality assurance’s critical role in adoption, acceleration of metal additive manufacturing (AM)
- SGLB’s PrintRite3D(R) is the only known technology that uniquely detects, identifies defects and anomalies real-time during 3D printing process of metal parts
- Sigma Labs looks to snag significant segment of an untapped $2 billion market
In a groundbreaking press release (http://nnw.fm/mCZ4f), Sigma Labs Inc. (NASDAQ: SGLB) announced a joint sales agreement to commercialize SGLB’s PrintRite3D Quality Assurance technology which has been integrated with the Materialise Control Platform. Materialize NV (NASDAQ: MTLS) is a recognized global leader in 3D-printing software and advanced 3D printing services. The widely used Materialise Control Platform is an embedded hardware and software solution that provides better control over the additive manufacturing (AM) process by giving full control to the end-user.
Just last November, Sigma Labs demonstrated the latest version of its proprietary PrintRite3D Real-Time Melt Pool Analytics software platform in conjunction with Materialise at the Formnext 2019 conference in Frankfurt (http://nnw.fm/9ui8U). Since then, the companies have achieved integration of their products and now will offer a unique product solution for the entire metal additive manufacturing market: the retrofit of existing AM machines, OEM machine integration and closed loop control.
A myriad of variables, from machines to materials, create production challenges in AM. The inability to know the quality of finished products until postproduction and the uncertainty of parts being produced with consistency has limited companies’ ability to scale and has severely limited the widespread adoption of additive manufacturing.
Sigma Labs is determined to change that uncertainty by using artificial intelligence (AI) to predict flaws in the meltpool during production, providing quality assurance in-process, rather than post-process. Sigma’s PrintRite3D uniquely leverages thermal signatures to monitor the quality of each part in the production process – layer by layer and in real time. This allows operators to correct or stop production of a defective part, resulting in reduced error rates and higher yields. This incredibly sophisticated and powerful technology holds tremendous value for the 3D metal printing industry, and the Materialise agreement is a clear recognition of the value.
The agreement marks the first time a 3rd party in-process quality assurance software has been integrated and embedded in an AM platform, and perhaps more importantly, the agreement also marks the launch of Sigma Labs into commercialization. Founded in 2010 by a team of Los Alamos scientists, physicists and metallurgists, Sigma Labs has undergone extensive testing and validation of efficacy, earning high marks from all parties along the way.
SGLB is in an enviable position with a market projected to exceed $2 billion dollars, based on just the estimated number of 3D metal printers shipped between 2021 and 2027. Even more significant is Sigma’s competitive role in the $2 billion market, as no comparable is known to exist. Sigma Labs is the sole provider of real-time, in-process quality control software for the metal additive manufacturing market. Beyond the looming existing market, 3D printing is booming and projected to grow at a CAGR of 32.5% from 2019 to 2020 – and Sigma should be able ride the crest of that wave as well.
A large untapped market in search of solutions, a big technological head start, strategic partnerships and alliances in place, multiple patents awarded with more pending, and a reputation as the leading technology with significant barriers to entry from competition, Sigma Labs now surges to expand commercialization.
For more information about Sigma Labs, please visit www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 11, 2020
- Pioneering supplier-to-pharmacy tech platform builder Trxade Group Inc. helps small, community-based pharmaceutical businesses be competitive with larger chains by sourcing drugs at discount prices and promoting transparency in business operations
- Trxade Group has been developing its subscribers’ access to licensed medical professionals through telehealth services that are both convenient to the patient and significant in their ability to limit the number of people visiting hospitals and offices
- Amid the sweeping, deadly impact of the seasonal flu and the rising novel coronavirus epidemic, Trxade’s online access to physicians is a timely preventative service
- Trxade Group Inc. recently announced its uplisting to the Nasdaq Capital Market and rang the exchange’s opening bell, changing its ticker from ‘TRXD’ to ‘MEDS’
- The company’s network of pharmaceutical partners continues to grow, serving a large percentage of the nation’s 24,000 independent pharmacies
Innovative B2B health services provider Trxade Group Inc. (NASDAQ: MEDS) is helping to reduce exposure to deadly viruses sweeping the planet through the patient empowerment actions of its wholly owned subsidiaries.
As seasonal flu virus infections continue to claim the lives of tens of thousands of Americans and hospitalizes hundreds of thousands of people worldwide (http://nnw.fm/vsI9O), the rise and spread of the novel coronavirus COVID-19 has drawn attention to international measures to stop a deadly, vaccine-less illness by first locking down an entire province (in China), and most recently an entire nation (in Italy), while other communities worldwide close public gathering venues or attempt to assure attendees that adequate health measures are being taken to limit their exposure to such viruses (http://nnw.fm/6ASjE).
Trxade Group’s support of community-based, independent pharmacies, as well as the acquisition of Community Specialty Pharmacy’s online access operation last year (http://nnw.fm/lIW5E) and the establishment of the “Bonum Health Hub” online portal initiative this year (http://nnw.fm/7Xw4G) seems almost prescient in nature given the viral outbreaks’ impact even on access to hospital facilities and their providers (http://nnw.fm/wHRR5).
On March 10, Trxade Group announced the launch of a new membership service by its virtual healthcare subsidiary Bonum Health and its DelivMeds concierge medication delivery operation. The new service allows subscribers to obtain three premium medical teleconferencing visits and free prescription delivery per month, according to a company news release (http://nnw.fm/d32UE).
Bonum’s telehealth services utilize patients’ personal smart tech devices in a private, HIPPA compliant manner that delivers access to board-certified physicians from virtually anywhere the patient may choose to be.
“Teleconferencing with a board-certified provider for assurance via online consultation is quick, easy, and relatively inexpensive. These services free patients from unnecessary exposure or resorting to urgent care facilities and hospital emergency rooms,” Trxade Group’s news release states. “With the seasonal flu outbreaks and the current coronavirus surge, patients are quick to brush off common symptoms, including cough, fever and body aches, as signs of a common cold; Telemedicine removes the barrier of self-doubt and complacency in the current climate of world-wide viral infections.”
Trxade Group is building a growing platform of integrated drug procurement, delivery and healthcare services to facilitate price transparency and increased profit margins for independent pharmacies within its network as well as pharmaceutical product sellers.
The company recently uplisted its common stock to the Nasdaq Capital Market, while also announcing it expected gross proceeds of $5.2 million from the sale of common stock in a public offering (http://nnw.fm/Yhg4C).
For more information, visit the company’s website at www.TrxadeGroup.com
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
March 11, 2020
- Sigma Labs, Materialise joint sales agreement calls for product commercialization
- Earlier MOU outlined integration of Materialise MCP Controller, SGLB PrintRite3D(R) technology
- Exclusive product expected to lower additive manufacturing costs, improve yield and profit margin, lead to closed loop control
Sigma Labs Inc. (NASDAQ: SGLB), the only provider of in-process, quality-assurance software to the commercial 3D-metal- printing industry, has entered into a joint sales agreement with Materialise, a leading provider of additive manufacturing software and sophisticated 3D-printing services (http://nnw.fm/s7JCy).
An earlier memorandum of understanding provided a framework for the two companies to cooperate on the integration of the widely used Materialise MCP Controller with Sigma Labs’ PrintRite3D(R) technology, together creating an integrated PrintRite3D and Materialise Control Platform (MCP) product. The companies have now achieved integration and will begin offering a unique product solution for retrofit of existing machines, OEM machine integration and closed loop control. Commercialization of the 3D printing industry’s first in-process quality control software is expected to commence immediately.
“Growing our partnership with Materialise is a significant milestone for Sigma Labs as we expand our footprint in the market and add momentum to our quest to broaden industry access to our groundbreaking PrintRite3D software,” SGLB Executive Chairman Mark K. Ruport stated in a news release. “The alignment is a natural step for both companies, as Materialise has a strong presence in the additive manufacturing market and a reputation for quality products. Commercializing and jointly selling this integrated solution will benefit both companies as well as advance the forward momentum of innovation in the 3D-manufacturing industry.”
SGLB scientists, engineers and software developers developed proprietary hardware and software technology that uses thermal readings to detect and predict anomalies during the 3D-printing process. This technology, incorporated in Sigma Labs’ PrintRite3D software, features real-time monitoring, analysis, feedback and control that delivers impressive results.
When utilizing the software, end users can lower their additive manufacturing costs and improve yield and profit margin. The MCP is an embedded hardware and software solution that addresses the growing need for broader and more straightforward control over the additive manufacturing process by giving full control to the end-user.
Materialise brings together three decades of 3D-printing experience into a range of software solutions and 3D-printing services, which together form the backbone of the 3D-printing industry. Materialise’s open and flexible solutions enable players in a variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D-printing applications designed to make the world a better and healthier place. Headquartered in Belgium with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D-printing facilities in the world.
Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D-advanced manufacturing technologies. SGLB’s advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.
For more information about Sigma Labs, please visit www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
